{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:53:10Z","timestamp":1785369190086,"version":"3.55.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/inf.0000000000000214","type":"journal-article","created":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T08:16:55Z","timestamp":1388564215000},"page":"608-616","source":"Crossref","is-referenced-by-count":25,"title":["Prognosis of Children With HIV-1 Infection Starting Antiretroviral Therapy in Southern Africa"],"prefix":"10.1097","volume":"33","author":[{"given":"Mary-Ann","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Bolton-Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleophas","family":"Chimbetete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Eley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Garone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Giddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Moultrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ndirangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Phiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Rabie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-G\u00fcnter","family":"Technau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Boulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-15-20210202","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/cid\/cir898","article-title":"ANRS 12222 MorbidityMortality Study Group. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote dIvoire.","volume":"54","author":"Anglaret","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R3-15-20210202","first-page":"730","article-title":"International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration.","volume":"99","author":"Davies","year":"2009","journal-title":"S Afr Med J"},{"key":"R4-15-20210202","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.298.16.1888","article-title":"Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia.","volume":"298","author":"Bolton-Moore","year":"2007","journal-title":"JAMA"},{"key":"R5-15-20210202","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1473-3099(08)70180-4","article-title":"Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa.","volume":"8","author":"Sutcliffe","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R7-15-20210202","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1086\/524686","article-title":"HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS); Concerted Action on Sero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.","volume":"197","author":"Dunn","year":"2008","journal-title":"J Infect Dis"},{"key":"R8-15-20210202","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/01.qai.0000242454.97650.72","article-title":"Simple Pediatric AIDS Severity Score (PASS): a pediatric severity score for resource-limited settings.","volume":"43","author":"Patel","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-15-20210202","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"R11-15-20210202","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(10)60666-6","article-title":"IeDEA Southern Africa and West Africa. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.","volume":"376","author":"May","year":"2010","journal-title":"Lancet"},{"key":"R12-15-20210202","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","article-title":"Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.","volume":"21","author":"May","year":"2007","journal-title":"AIDS"},{"key":"R14-15-20210202","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1097\/00002030-200409240-00006","article-title":"Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote dIvoire.","volume":"18","author":"Fassinou","year":"2004","journal-title":"AIDS"},{"key":"R16-15-20210202","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2989\/AJAR.2009.8.3.9.930","article-title":"Paediatric antiretroviral treatment programmes in sub-Saharan Africa: a review of published clinical studies.","volume":"8","author":"Davies","year":"2009","journal-title":"Afr J AIDS Res"},{"key":"R17-15-20210202","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1542\/peds.2009-2701","article-title":"Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries.","volume":"127","author":"Peacock-Villada","year":"2011","journal-title":"Pediatrics"},{"key":"R18-15-20210202","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/cid\/cis797","article-title":"DART and ARROW trial teams. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.","volume":"55","author":"Walker","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R19-15-20210202","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0b013e3181b9869f","article-title":"Pediatric AIDS Clinical Trials Group219219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.","volume":"53","author":"Brady","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-15-20210202","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/QAI.0b013e3181e0c4cf","article-title":"International epidemiologic Databases to Evaluate AIDS in Southern Africa. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa.","volume":"54","author":"Fenner","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-15-20210202","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/QAI.0b013e318183a92a","article-title":"Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children.","volume":"49","author":"Musoke","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-15-20210202","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/ije\/dyr080","article-title":"Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa.","volume":"41","author":"Egger","year":"2012","journal-title":"Int J Epidemiol"},{"key":"R26-15-20210202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1536867X0400400301","article-title":"Multiple imputation of missing values.","volume":"4","author":"Royston","year":"2004","journal-title":"Stata J"},{"key":"R27-15-20210202","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1536867X0800700401","article-title":"Multiple imputation of missing values: further update of ice, with an emphasis on interval censoring.","volume":"7","author":"Royston","year":"2009","journal-title":"Stata J"},{"key":"R28-15-20210202","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"R29-15-20210202","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: Issues and guidance for practice.","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"R30-15-20210202","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"R31-15-20210202","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/sim.1825","article-title":"ART Cohort Collaboration. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy.","volume":"23","author":"May","year":"2004","journal-title":"Stat Med"},{"key":"R32-15-20210202","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/sim.1691","article-title":"Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer.","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"key":"R33-15-20210202","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/sim.1621","article-title":"A new measure of prognostic separation in survival data.","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"key":"R34-15-20210202","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1536867X0600600105","article-title":"Explained variation for survival models.","volume":"6","author":"Royston","year":"2006","journal-title":"Stata J"},{"key":"R35-15-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/146532807X170448","article-title":"Antiretroviral therapy for children: challenges and opportunities.","volume":"27","author":"Eley","year":"2007","journal-title":"Ann Trop Paediatr"},{"key":"R36-15-20210202","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/QAI.0b013e3182167f0d","article-title":"Wamepotea (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya.","volume":"57","author":"Braitstein","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R37-15-20210202","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2334-11-31","article-title":"Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi.","volume":"11","author":"Weigel","year":"2011","journal-title":"BMC Infect Dis"},{"key":"R38-15-20210202","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/QAI.0b013e31827b70bf","article-title":"International IeDEA Pediatric Working Group1. Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration.","volume":"62","author":"Leroy","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R41-15-20210202","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa0800971","article-title":"CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants.","volume":"359","author":"Violari","year":"2008","journal-title":"N Engl J Med"},{"key":"R42-15-20210202","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1097\/QAI.0b013e3182303c7e","article-title":"Temporal trends in baseline characteristics and treatment outcomes of children starting antiretroviral treatment: an analysis in four provinces in South Africa, 2004-2009.","volume":"58","author":"Fatti","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R43-15-20210202","doi-asserted-by":"crossref","first-page":"e81037","DOI":"10.1371\/journal.pone.0081037","article-title":"Temporal Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in Southern Africa: The IeDEA-SA Collaboration.","volume":"8","author":"Davies","year":"2013","journal-title":"PLoS One"},{"key":"R44-15-20210202","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/QAI.0b013e3182060610","article-title":"International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Virologic failure and second-line antiretroviral therapy in children in South Africa-the IeDEA Southern Africa collaboration.","volume":"56","author":"Davies","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R45-15-20210202","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1753-4887.2001.tb06963.x","article-title":"Micronutrients and child health: studies in international nutrition and HIV infection.","volume":"59","author":"Duggan","year":"2001","journal-title":"Nutr Rev"},{"key":"R46-15-20210202","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1086\/515396","article-title":"CHAP Team. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children.","volume":"44","author":"Walker","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R47-15-20210202","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa1113249","article-title":"Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.","volume":"366","author":"Violari","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:02:31Z","timestamp":1620954151000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201406000-00015"}},"subtitle":["A Collaborative Analysis of Treatment Programs"],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000214","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}